"Dual acting cancer therapeutics targeting
solid tumors"
About SOLID
SOLID Therapeutics is an early-stage oncology company which is based on research at University of Copenhagen joining expertise in metabolite GPCR structure-based drug discovery in the Schwartz-Frimurer labs at the Novo Nordisk Foundation (NNF) Center for Basic Metabolic Research (CBMR) with the deep insight into cell biology of the tumor microenvironment in the Falsig Petersen lab. The concept of HCAR1 antagonists as anti-cancer drugs was supported by an Exploratory Pre-Seed grant from NNF, a Pre-Seed grant from the Bioinnovation Institute (BII) and an Innobooster grant from Innovationsfonden. The company was officially founded in March 2022 when accepted into the Venture Lab at BII.
"WE AIM TO DELIVER NOVEL CANCER THERAPEUTICS
WITH DUAL MODE OF ACTION TARGETING
BOTH CANCER CELLS AND IMMUNE CELLS"
The SOLID Team
The SOLID Board of Directors
ONE target - TWO mechanisms
.png)
A hallmark of solid tumors is the hypoxic and acidic microenvironment rich in lactate, which today is known to act as a signaling molecule sensed by the HCAR1/GPR81 receptor. HCAR1 expression is normally highly tissue restricted but is strongly induced by the tumor microenvironment in basically all types of solid tumors including hard-to-treat cancers. Importantly, high HCAR1 expression is associated with poor survival in e.g., breast and pancreatic cancer patients.
HCAR1 is expressed both on cancer cells and anti-cancer immune cells. HCAR1 improves survival of cancer cells by reprogramming their metabolism and upregulating defense mechanisms such as angiogenesis and check-point ligands. Importantly, HCAR1 is also involved directly in immune evasion by decreasing immune cell activation.
HCAR1 antagonists will therefore attack solid tumors in two ways by both directly impairing cancer cell survival and by stimulating tumor immunity.
Lundø et al. Cell Metabol. (2020) 31(4):666-668.
Figure created with BioRender.com
News
September 2024
SOLID Tx receives Innobooster grant from Innovation fund Denmark
Were thrilled to announce that Innovation Fund Denmark has awarded us an Innobooster grant!
This crucial support will accelerate the development of our first in class HCAR1 antagonists, bringing us one step closer to offering new hope to patients battling solid tumors.
We are very grateful to Innovation Fund Denmark for their continued support in our mission.
​
Read the MedWatch article here: MedWatch article
​
​
January 2024
EIFO invests EUR 670K in SOLID Tx
We are excited to share that the The Export and Investment Fund of Denmark (EIFO) is investing a substantial €670K in SOLID Therapeutics.
Combined with the recent backing from BioInnovation Institutes Venture House and Innovationfund Denmark the EIFO investment will enable us to strengthen the SOLID team and reach the next major scientific milestones, on the road towards developing our novel treatments for solid tumors.
A big thanks to EIFO for joining SOLID – together we are committed to make a lasting impact!
​
Read the MedWatch article here:
November 2023
SOLID named one of "10 Danish Startups to Watch" by Sifted
SOLID was named as one of "10 Danish Startups to Watch" by Sifted.
The list was put together with investors from Climentum Capital, byFounders and Novo Holdings.
​
Read the full article here: Sifted Article
​
Contact Us
Address
Ole Maaløes Vej 3, 1 floor
DK 2200 Copenhagen N
Denmark